- Home
- VYGR vs AWP Comparison
VYGR vs AWP Comparison
Compare VYGR & AWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- AWP
- Stock Information
- Founded
- VYGR 2013
- AWP 2007
- Country
- VYGR United States
- AWP United States
- Employees
- VYGR N/A
- AWP N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- AWP Trusts Except Educational Religious and Charitable
- Sector
- VYGR Health Care
- AWP Finance
- Exchange
- VYGR Nasdaq
- AWP Nasdaq
- Market Cap
- VYGR 342.5M
- AWP 352.4M
- IPO Year
- VYGR 2015
- AWP N/A
- Fundamental
- Price
- VYGR $5.75
- AWP $3.92
- Analyst Decision
- VYGR Strong Buy
- AWP
- Analyst Count
- VYGR 9
- AWP 0
- Target Price
- VYGR $16.44
- AWP N/A
- AVG Volume (30 Days)
- VYGR 485.6K
- AWP 331.5K
- Earning Date
- VYGR 11-12-2024
- AWP 01-01-0001
- Dividend Yield
- VYGR N/A
- AWP 12.48%
- EPS Growth
- VYGR N/A
- AWP N/A
- EPS
- VYGR 0.47
- AWP N/A
- Revenue
- VYGR $163,784,000.00
- AWP N/A
- Revenue This Year
- VYGR N/A
- AWP N/A
- Revenue Next Year
- VYGR N/A
- AWP N/A
- P/E Ratio
- VYGR $12.33
- AWP N/A
- Revenue Growth
- VYGR 3.40
- AWP N/A
- 52 Week Low
- VYGR $5.19
- AWP $3.06
- 52 Week High
- VYGR $11.72
- AWP $4.20
- Technical
- Relative Strength Index (RSI)
- VYGR 41.30
- AWP 31.95
- Support Level
- VYGR $6.08
- AWP $3.80
- Resistance Level
- VYGR $6.55
- AWP $4.43
- Average True Range (ATR)
- VYGR 0.35
- AWP 0.08
- MACD
- VYGR -0.05
- AWP -0.04
- Stochastic Oscillator
- VYGR 14.51
- AWP 20.69
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.